The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Remsima

100 milligram(s) Pdr/Conc/Soln for Infus

Celltrion Healthcare Hungary Kft.EU/1/13/853/001

Main Information

Trade NameRemsima
Active SubstancesInfliximab
Strength100 milligram(s)
Dosage FormPdr/Conc/Soln for Infus
Licence HolderCelltrion Healthcare Hungary Kft.
Licence NumberEU/1/13/853/001

Group Information

ATC CodeL04AB Tumor necrosis factor alpha (TNF-) inhibitors
L04AB02 infliximab

Status

Authorised/WithdrawnAuthorised
Licence Issued10/09/2013
Legal statusNot applicable
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back